Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02112474
Other study ID # MDT-HF-2013
Secondary ID NL43067.018.1320
Status Completed
Phase N/A
First received
Last updated
Start date November 13, 2014
Est. completion date November 30, 2018

Study information

Verified date November 2020
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Electrical stimulation of the spinal cord (Spinal Cord Stimulation or SCS) for pain relief has been used for decades. It is used most commonly in patients with chronic neuropathic leg pain, after spinal surgery. Conventional neurostimulation is applied in frequencies of 30 to 60 Hertz (Hz) and perceptible paraesthesias are felt. Stimulation using higher frequencies with sub perception paraesthesias has recently challenged the conventional form of neurostimulation.The high frequency stimulation appears to show better pain relief for both back and limb pain in comparison to low frequency SCS, and may also to be effective in some subjects who did not respond to low frequency SCS.


Description:

Rationale: Electrical stimulation of the dorsal columns of the spinal cord (Spinal Cord Stimulation or SCS) for pain relief has been used in humans for several decades. The most common indication for SCS is the treatment of refractory neuropathic leg pain, particularly when these symptoms persist after an anatomically successful operation (Failed Back Surgery Syndrome or FBSS). Low frequency - conventional - SCS (LF-SCS) is applied in frequencies ranging from 30 to 60 Hertz (Hz) and the subject feels paraesthesias in the painful area, which is considered the ideal situation. Recently, LF-SCS has been challenged by the development of stimulation modes at higher frequencies which provide pain relief at sub-perception threshold, i.e. without paraesthesias. A recent case series reported that High Frequency Spinal Cord Stimulation (HF-SCS) appears to show better pain relief for both back and limb pain in comparison to LF-SCS, and also to be effective in some subjects who did not respond to LF-SCS. Objective: The primary objective of this trial is to compare pain suppression in two groups of subjects with chronic unilateral limb pain as a result of FBSS . Study design: A prospective, double blind (subject, physician, statistician), multi-centre, randomized, crossover trial of SCS in the treatment of subjects with refractory neuropathic leg pain after back surgery. Study population: Patients with chronic neuropathic refractory unilateral leg pain Intervention: Patients will undergo neurostimulation with low and high frequency parameters, the order in which they receive treatment will be randomized Main study endpoint: Pain suppression in the short and long-term (24 days and 12 months) Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Both methods of stimulation are standard clinical practice performed routinely in the study centres, both groups will receive this standard care. The only difference is change of stimulation frequency and the order in which it is applied. Possible benefit to the subject is that both forms of stimulation will be evaluated. This may lead to a better quality of life in the HF-SCS Group as result of pain relief without paraesthesias. Furthermore, non-responders to LF-SCS may benefit from HF-SCS.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date November 30, 2018
Est. primary completion date November 17, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Male/female, 18 years to 70 years - Chronic, persistent, refractory, unilateral neuropathic limb pain, as a result of spinal surgery - Failed conservative treatments for chronic pain including but not limited to pharmacological therapy, physical therapy and minimally interventional pain procedures for chronic pain - Pain radiating in the leg, following segments L4 and/or L5 and/or S1 for at least 6 months - Minimum baseline pain intensity as assessed by VAS of = 50mm on 100mm scale in the primary pain area - Subject is able and willing to provide informed consent - Subject is able and willing to comply with the protocol and follow-up schedule - Subject has been included for implantation according to standard criteria from the Dutch Neuromodulation Society Exclusion Criteria: - Back pain component of more than 20% or VAS > 40mm on 100mm scale - Bilateral limb pain - Subjects with a previous SCS implantation. - Changes in pain medication in the 2 months preceding the trial period; - Expected inability of subjects to correctly operate the neurostimulation system - Presence of any other clinically significant or disabling chronic pain condition -eg. hip arthrosis, rheumatoid arthritis, fibromyalgia, etc. - History of coagulation disorders, lupus erythematosus, diabetes mellitus, or morbus Bechterew - Symptoms or proof of any malignant disease - Current use of medicines affecting coagulation which cannot be temporarily stopped - Evidence of an active disruptive psychiatric disorder or other known condition significant enough to impact the perception of pain, compliance to intervention and/or ability to evaluate treatment outcome as determined by the investigator - Life expectancy of less than 1 year - Existing or planned pregnancy in the trial period - BMI >20 and <35 - a minimum and maximum BMI limit are imposed due to the technical difficulties and risk of complications in underweight or morbidly obese subjects.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Spinal Cord Stimulation
Crossover design whereby subjects will undergo Spinal Cord Stimulation in two arms: low frequency stimulation and high frequency stimulation
Group 1
9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
Group 2
9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias

Locations

Country Name City State
Netherlands Medisch Centrum Alkmaar Alkmaar North Holland
Netherlands Academic Medical Center Amsterdam North Holland
Netherlands Alrijne Hospital Leiderdorp South Holland
Netherlands Rijnstate Hospital Velp Gelderland
Netherlands Diakonessenhuis Zeist Utrecht

Sponsors (5)

Lead Sponsor Collaborator
Jennifer Breel Alrijne Hospital, Diakonessenhuis, Utrecht, Noordwest Ziekenhuisgroep, Rijnstate Hospital

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Analog Pain Scores (VAS) 0mm to 10mm line scale, where higher score is better, measured 4 times a day at 09:00, 15:00, 21:00 and a nightscore measured first thing in the morning 24 days
Secondary Visual Analog Pain scores (VAS) 0mm to 10mm line scale, where higher score is better, measured 4 times a day at 09:00, 15:00, 21:00 and a nightscore measured first thing in the morning 12 months
Secondary EuroQoL 5Dimensions-3Levels Quality of LIfe, 5 questions measured on 3 levels (mild =1, moderate=2, severe=3). Higher score is worse. Each domain calculated according to a national index. 1 month, 12 months
Secondary Short Form-36 Quality of Life, 36 questions with differing formats, 8 domains, higher score is better 1 month, 12 months
Secondary Sleep questionnaire Quality of sleep before and after stimulation, Several Likert-type items 0-5 and 0-7, higher score is better 1 month, 12 months
Secondary GPES Subject satisfaction,1 Likert-type item 0-7, higher score is better 1 month, 12 months
Secondary Employment status Change in employment status, open question whether or not employment status has changed and how many hours per week persons were/not working 12 months
Secondary (Serious) Adverse Events Number of patients with device related events such as lead dislocation, infections, pocket pain, increase in pain whilst using one paticular frequency etc. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04699734 - Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Completed NCT05235191 - Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies Phase 3
Completed NCT05845177 - Persistent Pain After Hip Replacement
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Not yet recruiting NCT05949554 - Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
Withdrawn NCT05052645 - Ear Acupuncture for Neuropathic Pain N/A
Completed NCT02866396 - Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
Completed NCT02824588 - Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain N/A
Completed NCT02930551 - Neuromas as the Cause of Pain N/A
Active, not recruiting NCT02560545 - Cannabinoids Effects on the Pain Modulation System N/A
Enrolling by invitation NCT02485795 - Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management N/A
Completed NCT02099890 - The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury Phase 3
Not yet recruiting NCT02246517 - The Effect of N2O on Chronic Neuropathic Pain Patients Phase 0
Completed NCT01946555 - Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain N/A
Completed NCT01884662 - Virtual Walking for Neuropathic Pain in Spinal Cord Injury N/A
Completed NCT01718821 - Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients N/A
Completed NCT01669967 - The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin N/A
Completed NCT01201317 - A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy Phase 2
Completed NCT01207596 - Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain Phase 4